Self Study Module 3 - MedicalMinute: Case Discussion: HER2-Positive Breast Cancer With Brain Metastases

Launch Date:
May 25, 2022

Primary Audience:

Medical oncologists, Nurses, Nurse Practitioners, Pharmacists

Relevant Terms:

Breast cancer, HER2-positive breast cancer, Brain metastases, CNS metastases

In this module, Dr. Aditya Bardia describes the latest evidence on therapies that have demonstrated efficacy in targeting brain metastases, including small molecule inhibitors and antibody-drug conjugates.

Aditya Bardia, MD, MPH

Associate Professor, Medicine
Harvard Medical School
Attending Physician, Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Dr. Aditya Bardia is an Associate Professor in the Medicine Department at Harvard Medical School and Attending Physician at Massachusetts General Hospital Cancer Center, Boston, Massachusetts. He is the Director of Breast Cancer Research in Medical Oncology at Massachusetts General Hospital. He has led several high-impact clinical trials investigating novel therapies and translational studies in breast cancer including lead of the clinical development of the antibody drug conjugate, sacituzumab govitecan, now FDA-approved for triple-negative breast cancer. He is the author of more than 150 peer-reviewed papers. He is the recipient of Young Investigator Award from the ASCO Conquer Cancer Foundation and Career Catalyst Award for Susan G. Komen Foundation. Dr. Bardia is a faculty member of molecular tumor board by ASCO University and receipt of FASCO.
1.
Plan effective therapy for patients with HER2-positive MBC with or without CNS metastases incorporating existing and emerging targeted treatments